In yesterday’s Wall Street session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares traded at $9.37, down -1.16% from the previous session.
GLUE stock price is now 61.45% away from the 50-day moving average and 75.79% away from the 200-day moving average. The market capitalization of the company currently stands at $575.04M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $11, Wedbush recently initiated with Outperform rating for Monte Rosa Therapeutics Inc (NASDAQ: GLUE). On January 03, 2023, Wells Fargo Upgraded its previous ‘Equal Weight’ rating to ‘Overweight’ on the stock keeping its target price maintained at $18, while ‘UBS’ rates the stock as ‘Buy’
In other news, Wallace Owen B., Officer bought 20,000 shares of the company’s stock on Oct 28 ’24. The stock was bought for $240,000 at an average price of $12.00. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 20 ’24, 10% Owner Versant Venture Capital VI, L. sold 1,132,566 shares of the business’s stock. A total of $7,395,203 was realized by selling the stock at an average price of $6.53. This leaves the insider owning 5,099,336 shares of the company worth $47.78 million. A total of 27.35% of the company’s stock is owned by insiders.
During the past 12 months, Monte Rosa Therapeutics Inc has had a low of $2.77 and a high of $12.40. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 6.56, and a quick ratio of 6.56. The fifty day moving average price for GLUE is $5.8036 and a two-hundred day moving average price translates $5.330075 for the stock.
The latest earnings results from Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was released for 2024-06-30. The net profit margin was -2264.53% and return on equity was -59.51% for GLUE.
